The Pennant Group (NASDAQ:PNTG – Get Free Report) and biote (NASDAQ:BTMD – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.
Risk & Volatility
The Pennant Group has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, biote has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500.
Earnings and Valuation
This table compares The Pennant Group and biote”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| The Pennant Group | $947.71 million | 1.54 | $29.58 million | $0.90 | 46.53 |
| biote | $192.22 million | 0.20 | $27.05 million | $0.11 | 9.73 |
The Pennant Group has higher revenue and earnings than biote. biote is trading at a lower price-to-earnings ratio than The Pennant Group, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
85.9% of The Pennant Group shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 6.9% of The Pennant Group shares are held by company insiders. Comparatively, 32.4% of biote shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares The Pennant Group and biote’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| The Pennant Group | 2.93% | 10.33% | 4.20% |
| biote | 3.19% | -22.33% | 12.10% |
Analyst Recommendations
This is a summary of recent recommendations for The Pennant Group and biote, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| The Pennant Group | 0 | 1 | 5 | 0 | 2.83 |
| biote | 1 | 1 | 1 | 1 | 2.50 |
The Pennant Group currently has a consensus price target of $46.00, suggesting a potential upside of 9.84%. biote has a consensus price target of $2.50, suggesting a potential upside of 133.64%. Given biote’s higher probable upside, analysts plainly believe biote is more favorable than The Pennant Group.
Summary
The Pennant Group beats biote on 9 of the 15 factors compared between the two stocks.
About The Pennant Group
The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support. The company operates home health, hospice, and home care agencies, as well as senior living communities throughout Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.
About biote
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
Receive News & Ratings for The Pennant Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Pennant Group and related companies with MarketBeat.com's FREE daily email newsletter.
